At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

CLICK HERE FOR CME CREDIT

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Samuel Goldhaber, MD

Samuel Goldhaber, MD

Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Medicine Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA USA